Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome
Depression and fibromyalgia syndrome are debilitating chronic conditions that impose a significant burden on individuals, families and society. Both depression and fibromyalgia have many overlapping symptoms, and antidepressants of several classes are among recommended treatment options for patients with fibromyalgia syndrome. Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treatment of depression. The drug’s efficacy and safety have also been demonstrated, more recently, in the treatment of fibromyalgia syndrome. Pirlindole has a favourable tolerability profile, with no deleterious effect on cardiovascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Because of its specific and reversible inhibition of MAO-A and relatively short elimination half-life, no tyramine or ‘cheese’ effect is likely after short or long-term administration. The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome.
KeywordsFibromyalgia Amitriptyline Beck Depression Inventory Moclobemide Hamilton Depression Rate Scale
Jaime C. Branco has been a consultant and investigator in clinical trials conducted by Pierre-Fabre, is an investigator in clinical trials by Bial, and has participated in Pfizer’s and Lilly’s international advisory boards. Manuel R. Cruz has acted as Director of the Forensic Psychiatry Service and is a member of the Portuguese Group of Psychiatry Consilii (GPPCL), for which he is also a liaison officer, and the Portuguese Association Gerontopsiquiatria (APG). Augusto Filipe and Ana Maria Tomé are employees of Grupo Tecnimede, the company that markets pirlindole in Portugal.
We thank Liliana Coelho for assistance in the management of the manuscript preparation and bibliographic research. We also thank Ray Hill of inScience Communications, a Wolters Kluwer business, who provided medical writing support funded by Grupo Tecnimede, Sintra, Portugal.
- 1.National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (updated edition). CG90. London, UK: The British Psychological Society and the Royal College of Psychiatrists, 2009Google Scholar
- 6.Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12(2): e1–14Google Scholar
- 16.Storosum JG, Elferink AJ, van Zwieten BJ. Schizophrenia: do we really need placebo-controlled studies? Eur Neuro-psychopharmacol 1998 Dec; 8(4): 279–86Google Scholar
- 17.World Health Organization. Global Health Risks: mortality and burden of disease attributable to selected major risks. Geneva: WHO Press, 2009Google Scholar
- 22.Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association (APA), 2010Google Scholar
- 31.Silverstone T. Introduction to a new generation of antidepressant drugs: pirlindol. Psicopatologia (Madrid) 1987; 7(3): 432–6Google Scholar
- 38.Pentafarma, Sociedade Técnico-Medicinal, SA (Grupo Tecnimede). Pirlindol, summary of product characteristics. Abrunheira; 2009Google Scholar
- 39.Bruhwyler J, Monseu MJ, Vandekerckhove K, et al. Pirlindole, a reversible and selective monoamine oxidase A inhibitor: a retrospective evaluation of its clinical antidepressant profile. Eur J Clin Res 1997; 9: 1–21Google Scholar
- 40.Ehlers T, Ritter M. Placebo-controlled investigation of the effects of pirlindole on sensorimotor performance and subjective condition in comparison to imipramine and under the influence of ethanol. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 245–51CrossRefGoogle Scholar
- 44.Leydhecker W. Effect of a single dose of 225mg pirlindole on intraocular pressure and diameter of pupils in 10 patients with eye disease without primary raise in intraocular pressure. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 337–44CrossRefGoogle Scholar
- 49.Schwarz JA, Neumann H, Kalhammer R. Efficacy and tolerance of pirlindole in 20 male in-patients with psychosis; organic brain dysfunction and accompanying depression. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 277–82CrossRefGoogle Scholar
- 51.Nahunek K, Rysanek R, Svestka J, et al. Clinical trial of pyrazidol in endogenous depressive states. Activ Nerv Sup (Praha) 1980; 22(3): 170–1Google Scholar
- 54.Blaha L. A double-blind comparative study of pirlindole and amitriptyline in thirty depressive patients. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York (NY): Plenum Press, 1983: 303–9Google Scholar
- 56.Saletu B, Grunberger J, Rajna P, et al. Examining pharmaco EEG-based predictions about the antidepressant action of pirlindol by double blind clinical trials. In: Pichot P, Berner P, Wolf R, et a1., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 291–6CrossRefGoogle Scholar
- 57.Lehmann E, Kinzler E, Stuckman A, et al. A double-blind comparative study on the use of 225mg pirlindole and 150mg desipramine in the treatment of depressive inpatients. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 321–7CrossRefGoogle Scholar
- 59.DeWilde J, Mertens C, Van Dorpe J, et al. Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmacol 1997; 12: 41–6Google Scholar
- 61.Geerts S, Vandekerckhove K, Bruhwyler J, et al. Study report. Pirlindole versus fluoxetine in the treatment of major depression: a controlled double-blind medium-term study. Sintra: Grupo Tecnimede, 1999. (Data on file)Google Scholar
- 65.Derogatis LR. The SCL-90-R Manual: scoring, administration and procedures for the SCL-90-R. Baltimore (MD): Clinical Psychometric Research, 1977Google Scholar